Mirati Therapeutics, Inc.
PRC2 Inhibitors
Last updated:
Abstract:
The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
29 Jan 2019
Issue date:
4 Feb 2021